- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04820764
EFS of the CardioMech MVRS
February 9, 2024 updated by: CardioMech AS
Early Feasibility Study of the CardioMech Mitral Valve Repair System (MVRS)
Safety and performance evaluation of the CardioMech Mitral Valve Repair System (MVRS) in patients with degenerative mitral valve regurgitation.
Study Overview
Detailed Description
The purpose of the clinical study is to obtain clinical data on the CardioMech Mitral Valve Repair System (MVRS) in patients diagnosed with moderate to severe (≥3+) or severe (≥4+), symptomatic, degenerative mitral regurgitation and who are determined to be at intermediate or high surgical risk for mitral valve repair, as assessed by the site's multidisciplinary heart team.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jennifer Ruether
- Phone Number: 651-428-4440
- Email: jennifer.ruether@cardiomech.com
Study Contact Backup
- Name: Rick Nehm
- Email: rick.nehm@cardiomech.com
Study Locations
-
-
California
-
Thousand Oaks, California, United States, 91360
- Recruiting
- Cardiovascular Institute of Los Robles Health System
-
Contact:
- Mane Arabyan
- Email: Mane.Arabyan@HCAHealthcare.com
-
Principal Investigator:
- Saibal Kar, MD
-
-
Kansas
-
Wichita, Kansas, United States, 67226
- Recruiting
- Ascension St. Francis via Christi
-
Principal Investigator:
- Bassem Chehab, MD
-
Contact:
- Meredith Thunberg, RN, BSN
- Email: Meredith.Thunberg@cckheart.com
-
Principal Investigator:
- Brett Grizzell, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Active, not recruiting
- Mayo Clinic
-
Saint Cloud, Minnesota, United States, 56303
- Recruiting
- CentraCare Heart & Vascular Center
-
Principal Investigator:
- Thom Dahle, MD
-
Contact:
- Peggy Dahl
- Email: DahlP@centracare.com
-
-
New York
-
New York, New York, United States, 10016
- Active, not recruiting
- NYU Langone
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Atrium Health Sanger Heart and Vascular Institute
-
Principal Investigator:
- Michael Rinaldi, MD
-
Contact:
- Dana Amaro, MS, RN
- Email: Dana.Amaro@atriumhealth.org
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Recruiting
- Ascension St. Thomas West
-
Principal Investigator:
- Evelio Rodriguez, MD
-
Contact:
- Bailey Segura
- Email: Bailey.Segura@ascension.org
-
Principal Investigator:
- Andrew Morse, MD
-
-
Utah
-
Murray, Utah, United States, 84107
- Active, not recruiting
- Intermountain Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Eighteen (18) years of age or greater
- Moderate to severe (≥3+) or severe (≥4+) mitral valve regurgitation (per American Society of Echocardiography (ASE) guidelines) due to mitral valve prolapse or flail
- Intermediate or high surgical risk for mitral valve repair
Exclusion Criteria:
- History of rheumatic heart disease
- History of prior endocarditis
- History of prior repair or replacement of the mitral valve, annuloplasty or valvuloplasty or has a left atrial appendage closure device
- Severely calcified mitral leaflet or has evidence of calcification in the grasping area of the leaflets that would prevent leaflet anchor positioning and deployment
- Complex mechanism of MR (leaflet perforation, severe leaflet calcifications, commissural extension, commissural prolapse, multiple flail or prolapsing segments, cleft) present on required imaging
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CardioMech Mitral Valve Repair System (MVRS)
|
CardioMech MVRS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in MR grade
Time Frame: 30 days
|
30 days
|
Freedom from serious adverse events determined to be related to the CardioMech MVRS device or procedure
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mathew Williams, MD, NYU Langone
- Principal Investigator: Mayra Guerrero, MD, Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2021
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
June 1, 2029
Study Registration Dates
First Submitted
March 25, 2021
First Submitted That Met QC Criteria
March 25, 2021
First Posted (Actual)
March 29, 2021
Study Record Updates
Last Update Posted (Actual)
February 12, 2024
Last Update Submitted That Met QC Criteria
February 9, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10228
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral RegurgitationUnited States
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Boston Scientific CorporationActive, not recruitingCardiovascular Diseases | Mitral Regurgitation Functional | Mitral Valve DiseaseUnited States, Australia
-
Abbott Medical DevicesActive, not recruitingHeart Failure | Mitral Regurgitation | Mitral Valve Regurgitation | Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure SubjectsUnited States, Canada
-
Mardil MedicalRecruitingFunctional Mitral RegurgitationCanada, Hungary, France, Germany, Netherlands, Panama, Poland
Clinical Trials on CardioMech MVRS
-
Edwards LifesciencesTerminatedMitral RegurgitationGermany, Netherlands, Austria, United Kingdom
-
Edwards LifesciencesICON plcTerminatedSevere Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet ProlapseGermany, Spain, Switzerland